Teradyne rallies 4% early as UBS does a rare double rating upgrade
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
Longtime stoney fave--
Mimecast gains after company is said to be exploring a potential sale
Oct. 28, 2021 9:23 AM ET Mimecast Limited (MIME)
Mimecast gains after company is said to be exploring a potential sale
Oct. 28, 2021 9:23 AM ET Mimecast Limited (MIME)
DLA-
Delta Apparel had quite a run i do not know why but they are a mover in the retail space.
Triple top @$33
Down to $25
Now- $27
Delta Apparel had quite a run i do not know why but they are a mover in the retail space.
Triple top @$33
Down to $25
Now- $27
- Delta Apparel (DLA+1.9%)releases preliminary results for its fiscal quarter ended Oct 2, 2021.
- The company expects overall net sales to be approximately $114 million, a 6% Y/Y increase, and slightly ahead of consensus revenue of $113.4M. EPS are anticipated to be in range of $0.91 to $0.94 per diluted share which includes a valuation gain on contingent expectations vs consensus adjusted EPS of $0.65.
- "While our Delta catalog growth was constrained, particularly at the beginning of the quarter, from suboptimal inventory levels, our record-level manufacturing output allowed us to rebuild inventory as the quarter progressed. We expect this will continue through the first half of fiscal year 2022, positioning us for a strong spring selling season," said CEO Robert W. Humphreys.
- The company will hold its earnings call after the market close on Nov 18.//
ALDX up 3%
Is this good Stoney:
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the Fourth Quarter of 2021
Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa On Track to Initiate in the Fourth Quarter of 2021
Phase 2 Clinical Trial Results of ADX-629 in Multiple Systemic Indications Expected in the Fourth Quarter of 2021 or the First Quarter of 2022
Cash and cash equivalents as of September 30, 2021 were $241.4 million. Based on Aldeyra’s current operating plan, the company believes that existing cash and cash equivalents will be sufficient to fund currently projected operating expenses through the end of 2023, including potential New Drug Application submissions; initial commercialization of reproxalap, if approved; and continued development of the company’s product candidates in ocular and systemic immune-mediated diseases.
Is this good Stoney:
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the Fourth Quarter of 2021
Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa On Track to Initiate in the Fourth Quarter of 2021
Phase 2 Clinical Trial Results of ADX-629 in Multiple Systemic Indications Expected in the Fourth Quarter of 2021 or the First Quarter of 2022
Cash and cash equivalents as of September 30, 2021 were $241.4 million. Based on Aldeyra’s current operating plan, the company believes that existing cash and cash equivalents will be sufficient to fund currently projected operating expenses through the end of 2023, including potential New Drug Application submissions; initial commercialization of reproxalap, if approved; and continued development of the company’s product candidates in ocular and systemic immune-mediated diseases.
Matterport announces availability of Matterport for Mobile for Android users 09:19 MTTR Matterport announced that Matterport for Mobile now gives Android users worldwide the power to instantly create a dimensionally accurate digital twin of buildings and spaces with just the smartphone in their pocket. Now available in 175 countries in the Google Play app store, the company's breakthrough 3D capture app for Android taps into the platform's leading market share of the global mobile device market. With more than 6 billion active smartphones in the world today, Matterport aims to sharply accelerate its progress toward digitizing the built world.
Motorsport Games announces official launch of NASCAR 21: Ignition 09:13 MSGM Motorsport Games announces the official launch of NASCAR 21: Ignition, available to play today. The newest installment in the officially licensed NASCAR gaming franchise is available for Sony PlayStation 4, Microsoft Xbox One and PC through the Steam store. "NASCAR 21: Ignition is out and we couldn't be more excited to share our game with the fans," said Dmitry Kozko, CEO of Motorsport Games. "Our team has poured its passion into this game, along with adding Unreal Engine and rFactor physics, to create the most authentic, realistic and dynamic NASCAR simulation we've ever produced. Fans will truly be able to feel the thrill of getting behind the wheel and racing to glory in NASCAR 21: Ignition." NASCAR 21: Ignition is developed and published by Motorsport Games and is powered by Unreal Engine and Studio 397's rFactor physics engine. NASCAR 21: Ignition contains the official drivers, teams and tracks from the 2021 NASCAR Cup Series, including broadcast quality pre-race build up and post-race replays.
Motorsport Games announces official launch of NASCAR 21: Ignition 09:13 MSGM Motorsport Games announces the official launch of NASCAR 21: Ignition, available to play today. The newest installment in the officially licensed NASCAR gaming franchise is available for Sony PlayStation 4, Microsoft Xbox One and PC through the Steam store. "NASCAR 21: Ignition is out and we couldn't be more excited to share our game with the fans," said Dmitry Kozko, CEO of Motorsport Games. "Our team has poured its passion into this game, along with adding Unreal Engine and rFactor physics, to create the most authentic, realistic and dynamic NASCAR simulation we've ever produced. Fans will truly be able to feel the thrill of getting behind the wheel and racing to glory in NASCAR 21: Ignition." NASCAR 21: Ignition is developed and published by Motorsport Games and is powered by Unreal Engine and Studio 397's rFactor physics engine. NASCAR 21: Ignition contains the official drivers, teams and tracks from the 2021 NASCAR Cup Series, including broadcast quality pre-race build up and post-race replays.
ALDX up 3%
Is this good Stoney:
Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights
Company Expects to Report Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Clinical Trials of Reproxalap in Dry Eye Disease in the Fourth Quarter of 2021
Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa On Track to Initiate in the Fourth Quarter of 2021
Phase 2 Clinical Trial Results of ADX-629 in Multiple Systemic Indications Expected in the Fourth Quarter of 2021 or the First Quarter of 2022
Cash and cash equivalents as of September 30, 2021 were $241.4 million. Based on Aldeyra’s current operating plan, the company believes that existing cash and cash equivalents will be sufficient to fund currently projected operating expenses through the end of 2023, including potential New Drug Application submissions; initial commercialization of reproxalap, if approved; and continued development of the company’s product candidates in ocular and systemic immune-mediated diseases.
I think so. The problem is their most well thought of product does treat a rare disease.
Aldeyra received orphan drug designation for ADX-2191 from FDA.
There are no approved drug treatments for patients with RP, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. The disease affects an estimated 82,000-110,000 individuals in the United States, and approximately 1 in 4,000 people worldwide.
No treatment out there....so I like that 110,000 in US It's not a huge number but it could be just enough. Stick with it.
Yeah I remember reading that, but isn't one of them for a bigger target population?I think so. The problem is their most well thought of product does treat a rare disease.
Aldeyra received orphan drug designation for ADX-2191 from FDA.
There are no approved drug treatments for patients with RP, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. The disease affects an estimated 82,000-110,000 individuals in the United States, and approximately 1 in 4,000 people worldwide.
No treatment out there....so I like that 110,000 in US It's not a huge number but it could be just enough. Stick with it.
Same thing OCUL was going after, but a different approach.
get in van she going to rip!
Genius Brands International, Inc. (GNUS) This should gain 100% in 3 days.
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5850+0.0650 (+4.28%)
As of 9:59AM EDT.
Genius Brands International, Inc. (GNUS) This should gain 100% in 3 days.
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5850+0.0650 (+4.28%)
As of 9:59AM EDT.
I am watching it. I thought about it.get in van she going to rip!
Genius Brands International, Inc. (GNUS) This should gain 100% in 3 days.
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5850+0.0650 (+4.28%)
As of 9:59AM EDT.
Lets see what it does.
I need confirmation.